DDInter9 DDInter782
To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, and in adult patients with Mantle cell lymphoma (MCL) who have already received at least one prior therapy. In August 2022, the FDA approved a new tablet formulation of Calquence, enabling the co-administration of this drug with proton pump inhibitors (PPIs).[L42795,L42800] Unlike Calquence capsules, the co-administration of Calquence tablets and PPIs does not have an effect in the pharmacokinetics of
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Acalabrutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magaldrate
Acalabrutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivosidenib
Acalabrutinib {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Acalabrutinib {u} may lead to a major life threatening interaction when taken with {v} Binimetinib
Acalabrutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Flurbiprofen
Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate
Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Acalabrutinib may lead to a major life threatening interaction when taken with Idelalisib
Acalabrutinib may lead to a major life threatening interaction when taken with Binimetinib
Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Acalabrutinib may lead to a major life threatening interaction when taken with Flurbiprofen